


Rodríguez-Reyes M¹, Sotoca-Momblona JM¹, Soy-Muner D¹

¹Pharmacy Service. Division of Medicines. Hospital Clínic de Barcelona - Universitat de Barcelona

Background and Importance

- Co-administration of direct acting antivirals (DAA) with strong cytochrome P-450 inducing drugs, such as some antiepileptics, is contraindicated because it can result in virological failure.
- There is usually some reluctance to modify chronic antiepileptics therapy in patients with well-controlled seizures.
- This case report contributes to the limited literature regarding co-administration of sofosbuvir/velpatasvir and antiepileptic drugs¹.



Aim and Objectives

- ▶ To assess the efficacy of **sofosbuvir/velpatasvir** for 12 weeks in a patient taking the strong CYP inducing drugs **carbamazepine** and **phenobarbital**.

Materials and Methods

- Descriptive and retrospective clinical case. Data were obtained from electronic medical records.
- An undetectable RNA level 12 weeks after completion of therapy (SVR12) defines treatment success.

Results

- ▶ Three drug interactions were detected:

Drug	Effect	Action
Omeprazole	Reduction in antiviral concentrations	Omeprazole was administered 4h after antiviral drug
Carbamazepine	Reduction in antiviral concentrations	It was recommended not to change their anticonvulsant drugs, so sofosbuvir/velpatasvir was initiated
Phenobarbital		

- ▶ The treatment was well tolerated, adherence was correct and the patient has remained seizure-free.
- ▶ Viral load was undetectable at 4 weeks, 12 weeks and 24 weeks post-treatment initiation, therefore SVR12 was achieved.

Clinical characteristics of the patient	
Age (years)	54
Sex	Female
Fibrosis stage	F3
Previous antivirals	Naïve
Concomitant treatment	Carbamazepine, phenobarbital, clonazepam, topiramate, folic acid and omeprazole

Conclusion and Relevance

- Sofosbuvir/velpatasvir administered for 12 weeks in a patient on treatment with carbamazepine and phenobarbital achieved SVR12 despite the enzyme-inducing effect of antiepileptic drugs on the hepatitis C antiviral concentrations.

References

1. Marcos-Fosch C, et al. Anti-epileptic drugs and hepatitis C therapy: Real-world experience. J Hepatol 2021; 75(4):984-985.